GlobeNewswire

2024-09-18 23:07

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Br

SPRING, Texas, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., presented results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration with its clinical stage experimental therapeutic RXR agonist compound IRX4204. The presentation titled “The highly potent and selective third generation RXR nuclear receptor agonist compound IRX4204 has potential for prevention and treatment of normal aging-related neurodegeneration” was presented at the FASEB Research Conference on Cellular and Molecular Mechanisms of Brain Aging, being held in Niagara Falls, NY, USA. The presentation was authored by Vidyasagar Vuligonda, Ph.D., Chief Science Officer, and Martin E. Sanders, M.D., Chief Executive Officer.

Normal aging-related neurodegeneration is causally related to chronic low-grade inflammation in the brain, so called neuro-inflammaging. Neuro-inflammaging results in chronic loss of myelinated nerve fibers which conduct neuroelectric signals for communication between neurons. Over time, neuro-inflammaging also results in death of neurons. These natural processes start in the brains of normal healthy humans around the third decade of life, and progress with gradual decline of cognitive, memory, special senses, and physical functions through the remainder of life.

The studies showed that IRX4204 inhibits brain inflammation by decreasing production of the pro-inflammatory cytokine IL-6 by microglial cells. It also promotes growth of immunosuppressive regulatory Treg cells and inhibits Th17 cells from producing the pro-inflammatory cytokine IL-17. Thereby IRX4204 has pharmacologic mechanisms of action addressing two types of neuroinflammation observed in normal aging-related neurodegeneration. IRX4204 also promotes development of myelin-producing cells, which protect and repair damaged myelinated nerve fibers. Further, IRX4204 has direct effects on survival of neurons, and neurorestorative effects on neurons, by increasing their growth of neurites. These effects were observed with IRX4204 alone, and synergistically in combination with insulin, demonstrating IRX4204 has insulin sensitizing activity on neurons. Neuronal insulin insensitivity is a known contributing factor to brain aging. Cumulatively, these studies demonstrated that IRX4204 has benefit on multiple processes of normal brain aging, i.e., neuroinflammation, loss of myelinated nerve fibers, neuronal insulin insensitivity, loss of neuronal interconnections, and decreased neuron survival.

Dr. Vuligonda stated, “These findings support the potential of IRX4204 for prevention and treatment of normal aging-related neurodegeneration. Because we observed restoration of lost myelinated nerve fibers, and formation of new neurites, both of which could restore functional inter-neuronal communications, we believe that IRX4204 has potential for reversing to some degree the cognitive decline and other disabling manifestations of normal brain aging.”

Dr. Sanders stated “Io Therapeutics has previously observed promising potential benefit of IRX4204 in a pilot open-label clinical trial of IRX4204 in patients with Parkinson’s disease. The company is planning a placebo-controlled double-blind phase II clinical trial of IRX4204 in Parkinson’s disease, to be initiated in Q1 of 2025. We look forward to also conducting exploratory clinical trials of IRX4204 in individuals experiencing normal-aging related neurodegeneration.”

About Io Therapeutics: Io Therapeutics, Inc. is a privately held company headquartered in Spring, Texas. More information on Io Therapeutics and its product development programs is available on the company’s web site: www.io-therapeutics.com

Forward Looking Statements: This new release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.

Contact:
info@io-therapeutics.com

source: Io Therapeutics, Inc.

人氣文章
最近7天
1
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
2
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
3
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
4
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
5
港股 | 午市前瞻 | AI應用概念炒作有錢途 下階段部署邊隻好?
6
港股 | 蕭猷華:恒指短線回調,中線繼續看好
7
AI | DeepSeek日活躍用戶達二千萬,據報在港設兩公司
8
神州經脈 | 多國限制用DeepSeek,美郵政恢復收中港包裹
9
iPhone SE 4或於本周內上架官網
10
關稅戰 | 觸發避險金價屢創新高看3000美元,應揀買金礦股抑或黃金ETF?
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
3
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
6
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
7
一本萬利 | 2025年的五個「勿」(有片)
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
10
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
14
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
15
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
16
習近平應約與特朗普通電話,特:冀盡快與習見面
17
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
18
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
19
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
20
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
21
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
22
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
23
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
24
加州山火造成超500億美元損失,大量房主未買保險
25
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
26
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
27
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
28
特朗普就職 | 特朗普上台後行動列表
29
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
30
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

流感高峰期

山今養生智慧

輕鬆護老